The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 3 , Pages 591-599 , March 2010

Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2

Received 25 June 2009 ,Revised 4 September 2009 ,Accepted 3 October 2009.

References 

  1. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer. 2002;95:2096–2102
  2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  3. Maley CC. Multistage carcinogenesis in Barrett's esophagus. Cancer Lett. 2007;245:22–32
  4. Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFα. Eur J Cancer Prev. 2001;10:163–166
  5. Lee JS, Oh TY, Ahn BO, Cho H, Kim WB, Kim YB, et al. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat Res. 2001;480-481:189–200
  6. Babu A, Meng X, Banerjee AM, Gamboni-Robertson F, Cleveland JC, Damle S, et al. Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg. 2008;135:1220–1227
  7. Fijneman RJ, Cormier RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci. 2008;13:4144–4174
  8. Lagorce-Pages C, Paraf F, Wendum D, Martin A, Flejou JF. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus. Virchows Arch. 2004;444:426–435
  9. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods. 2006;3:109–116
  10. Cummings BS. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol. 2007;74:949–959
  11. Belinsky GS, Rajan TV, Saria EA, Giardina C, Rosenberg DW. Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog. 2007;46:106–116
  12. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet. 1997;17:88–91
  13. Fijneman RJ, Peham JR, van de Wiel MA, Meijer GA, Matise I, Velcich A, et al. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008;99:2113–2119
  14. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68:4277–4286
  15. Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol. 2000;165:2790–2797
  16. Kuwata H, Nakatani Y, Murakami M, Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem. 1998;273:1733–1740
  17. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology. 2005;128:1445–1461
  18. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55:115–122
  19. Piazuelo E, Jimenez P, Strunk M, Santander S, Garcia A, Esteva F, et al. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat. 2006;81:150–161
  20. Yu L, Wu WK, Li ZJ, Wong HP, Tai EK, Li HT, et al. E series of prostaglandin receptor 2–mediated activation of extracellular signal–regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma. J Pharmacol Exp Ther. 2008;327:258–267
  21. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis. 2006;27:1214–1221
  22. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res. 2004;10:6703–6709
  23. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005;26:785–791
  24. Xie Y, Liu L, Huang X, Guo Y, Lou L. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A2. J Pharmacol Exp Ther. 2005;314:1210–1217
  25. Xie Y, Yu Z, Liu L, Guo Y, Lou L. Biphasic regulation of extracellular signal-regulated kinases by scalaradial, a secretory phospholipase A(2) inhibitor. Cancer Biol Ther. 2006;5:988–992

 Disclosures: None.

 Supported by University of Colorado Academic Enrichment Funds.

PII: S0022-5223(09)01563-3

doi: 10.1016/j.jtcvs.2009.10.061

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 3 , Pages 591-599 , March 2010

Article Tools

* Image Usage & Resolution